Most interestingly, hybrids 14 , 22 and 23 showed an improved efficacy compare to the native peptide 1 (Fig
The practice of microdosing GLP-1 medications is mainly experimental and off-label
This excess risk stems from multiple factors including accelerated atherosclerosis, increased inflammatory state, abnormal blood clotting tendencies, and the metabolic damage caused by chronic hyperglycemia
Front Cell Dev Biol 2020;8:602574.ArticlePubMedPMC 38
4 For example, ADA and KDIGO joint group has recommended that for patients with T2DM and CKD who do not achieve their glycemic target with metformin and/or an SGLT2i or cannot use them, a GLP-1RAs with proven cardiovascular benefit is recommended
The TRIUMPH programme is collecting cardiovascular data alongside its weight-loss measures, and a dedicated outcomes trial is expected once retatrutide is approved